Clinical trial
Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing…
NCT00002456 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00002456 |
|---|---|
| Title | Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation |
| Official title | Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft Versus Host Disease, Leukemia, Lymphoma |
| Intervention type | Drug, Procedure |
| Interventions | cyclosporine, methotrexate, allogeneic bone marrow transplantation |
| Start date | May 1, 1986 |
| Completion | Apr 1, 2002 |
| First posted | Apr 26, 2004 |
| Last update posted | Nov 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: